Efficacy of a device to narrow the coronary sinus in refractory angina.

Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single-centre real-world experience. Neth Heart J (2016) 1.37

Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading? J Cardiovasc Transl Res (2015) 0.92

A device to narrow the coronary sinus for angina. N Engl J Med (2015) 0.88

A device to narrow the coronary sinus for angina. N Engl J Med (2015) 0.87

A device to narrow the coronary sinus for angina. N Engl J Med (2015) 0.86

A device to narrow the coronary sinus for angina. N Engl J Med (2015) 0.86

Angina treatments and prevention of cardiac events: an appraisal of the evidence. Eur Heart J Suppl (2015) 0.78

Cardiac shockwave therapy in patients with chronic refractory angina pectoris. Neth Heart J (2016) 0.76

Percutaneous Device to Narrow the Coronary Sinus: Shifting Paradigm in the Treatment of Refractory Angina? A Review of the Literature. Front Cardiovasc Med (2016) 0.75

Recent Publications by Ochsner Authors. Ochsner J (2015) 0.75

Potential relief for refractory angina. N Engl J Med (2015) 0.75

A device to narrow the coronary sinus for angina. N Engl J Med (2015) 0.75

Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. Eur Heart J Qual Care Clin Outcomes (2016) 0.75

Sneaking in through the back door. Neth Heart J (2017) 0.75

Coronary artery disease: Interventional narrowing of the coronary sinus in refractory angina. Nat Rev Cardiol (2015) 0.75

A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. PLoS One (2017) 0.75

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation (2006) 13.21

A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol (2009) 8.13

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet (2013) 7.54

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39

Circadian dependence of infarct size and left ventricular function after ST elevation myocardial infarction. Circ Res (2011) 5.87

ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol (2006) 5.70

Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol (2013) 5.11

Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol (2007) 4.62

Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA (2011) 4.52

Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med (2005) 4.45

Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ (2006) 4.36

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet (2012) 4.36

Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol (2012) 4.29

Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA (2012) 3.91

Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet (2013) 3.74

Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res (2011) 3.72

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med (2015) 3.69

ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)--summary of recommendations. J Vasc Interv Radiol (2006) 3.59

A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2008) 3.44

Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA (2012) 3.30

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17

Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation (2011) 3.16

Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol (2010) 3.07

Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem (2007) 3.06

Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation (2011) 2.98

Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol (2012) 2.97

Survival and cardiac remodeling benefits in patients undergoing late percutaneous coronary intervention of the infarct-related artery: evidence from a meta-analysis of randomized controlled trials. J Am Coll Cardiol (2008) 2.94

The role of trust in use of preventive services among low-income African-American women. Prev Med (2004) 2.90

"False-positive" cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction. JAMA (2007) 2.89

Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv (2010) 2.88

Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation (2007) 2.88

Myocardial injury and long-term mortality following moderate to severe carbon monoxide poisoning. JAMA (2006) 2.83

ST-elevation myocardial infarction diagnosed after hospital admission. Circulation (2014) 2.83

Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 2.82

2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2011) 2.71

Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J (2007) 2.63

A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med (2008) 2.60

Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation (2007) 2.59

Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis (2012) 2.38

Decision making in prostate cancer screening using decision aids vs usual care: a randomized clinical trial. JAMA Intern Med (2013) 2.38

Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol (2007) 2.34

Genetic variation in SCN10A influences cardiac conduction. Nat Genet (2010) 2.30

Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol (2008) 2.29

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J (2009) 2.29

Recommendations for the implementation of telemedicine within stroke systems of care: a policy statement from the American Heart Association. Stroke (2009) 2.26

Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol (2010) 2.23

Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol (2009) 2.23

A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J (2006) 2.22

Diagnostic performance of multislice spiral computed tomography of coronary arteries as compared with conventional invasive coronary angiography: a meta-analysis. J Am Coll Cardiol (2006) 2.22

Clinical features and outcomes of carotid artery stenting by clinical expert consensus criteria: a report from the CARE registry. Catheter Cardiovasc Interv (2010) 2.21

Cardiovascular manifestations of moderate to severe carbon monoxide poisoning. J Am Coll Cardiol (2005) 2.19

Questing for circadian dependence in ST-segment-elevation acute myocardial infarction: a multicentric and multiethnic study. Circ Res (2013) 2.13

Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients. Eur J Prev Cardiol (2012) 2.11

Automated 3D analysis of pre-procedural MDCT to predict annulus plane angulation and C-arm positioning: benefit on procedural outcome in patients referred for TAVR. JACC Cardiovasc Imaging (2013) 2.10

Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. Circ Cardiovasc Interv (2012) 2.07

Transcatheter treatment for refractory angina with the Coronary Sinus Reducer. EuroIntervention (2014) 2.07

All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet (2002) 2.05

Procedural variation in the performance of primary percutaneous coronary intervention for ST-elevation myocardial infarction: a SCAI-based survey study of US interventional cardiologists. Catheter Cardiovasc Interv (2013) 2.02

The impact of therapeutic hypothermia as adjunctive therapy in a regional primary PCI program. Resuscitation (2012) 1.97

Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation (2011) 1.95

Erythrocyte aggregation as a cause of slow flow in patients of acute coronary syndromes. Int J Cardiol (2011) 1.94

Natural history and management of aortocoronary saphenous vein graft aneurysms: a systematic review of published cases. Circulation (2012) 1.93

Luminal flow patterns dictate arterial drug deposition in stent-based delivery. J Control Release (2008) 1.90

Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol (2005) 1.90

Tissue engineering therapy for cardiovascular disease. Circ Res (2003) 1.87

Catheter-based treatment of the subclavian and innominate arteries. Catheter Cardiovasc Interv (2008) 1.86

Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res (2011) 1.85

Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). J Cardiovasc Transl Res (2010) 1.84

ACCF/SCAI/SVMB/SIR/ASITN 2007 clinical expert consensus document on carotid stenting: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting). J Am Coll Cardiol (2007) 1.78

The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation (2012) 1.75

Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. Circulation (2008) 1.74

Endovascular stenting for vertebral artery stenosis. J Am Coll Cardiol (2010) 1.74

Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv (2010) 1.74

Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation (2003) 1.72

Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation (2012) 1.70

Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol (2013) 1.70

Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. Am J Cardiol (2010) 1.66

Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res (2008) 1.64

A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther (2002) 1.63

Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis (2012) 1.63

Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Circulation (2013) 1.62

Increased prevalence of coronary artery aneurysms among cocaine users. Circulation (2005) 1.60

Rotational vs. standard coronary angiography: an image content analysis. Catheter Cardiovasc Interv (2009) 1.59

Chronic periodontitis, a significant relationship with acute myocardial infarction. Eur Heart J (2003) 1.57

A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial. Catheter Cardiovasc Interv (2012) 1.55

Immediate vs. delayed stenting in acute myocardial infarction: a systematic review and meta-analysis. EuroIntervention (2013) 1.55

Diagnostic yield of extensive infectious panel testing in acute pericarditis. Cardiology (2011) 1.55

Identification and predictive value of interleukin-6+ interleukin-10+ and interleukin-6- interleukin-10+ cytokine patterns in ST-elevation acute myocardial infarction. Circ Res (2012) 1.55

Arteriotomy closure devices for cardiovascular procedures: a scientific statement from the American Heart Association. Circulation (2010) 1.53

Elevated brain natriuretic peptide predicts blood pressure response after stent revascularization in patients with renal artery stenosis. Circulation (2005) 1.53

High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation acute myocardial infarction in 41% of cases: a multiethnic case-control study. J Am Coll Cardiol (2011) 1.53

Blood pressure response to renal artery stenting in 901 patients from five prospective multicenter FDA-approved trials. Catheter Cardiovasc Interv (2013) 1.52

Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol (2005) 1.52